Receives Funding from the California Institute for Regenerative Medicine (CIRM) to Advance SuperNova-1 and NeuroNova-2 Development Programs
Summary
The grant was awarded to City of Hope to support the manufacturing of the therapeutic agent, the conducting of the multi-center Phase 1 trial, and the determination of activity, biodistribution, immunogenicity, and preliminary clinical efficacy. The study received FDA authorization to proceed with a Phase 1 clinical trial, which will be led by principal investigator Jana Portnow, M.D., Professor in City of Hopes Department of Medical Oncology & Therapeutics Research and Co-Director of the Brain Tumor Program at City of Hope, one of the largest cancer research and treatment organizations in the United States and a founding member of the National Comprehensive Cancer Network. Calidi holds an exclusive worldwide licensing agreement for patents covering the NSC-CRAd-S-pk7 technology (NeuroNova).I am honored that CIRM has recognized the expertise City of Hope has in early-phase development of leading-edge therapies for brain tumors, Portnow said. We are pleased to receive the support of CIRM and the further endorsement of our NeuroNova platform and are excited for the continued advancement of this Phase 1 study with our partners at City of Hope.Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that is revolutionizing the effective delivery and potentiation of oncolytic viruses for targeted therapy against difficult-to-treat cancers. Calidis off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses currently in development leading to enhanced efficacy and improved patient safety.